<DOCUMENT>
<TYPE>EX-10.8.I
<SEQUENCE>15
<FILENAME>b323607ex10-8i.htm
<DESCRIPTION>AMENDMENT AGREEMENT TO AMEND THE 01/24/00
<TEXT>
<html>
<head>
<title>
Prepared and filed by St Ives Burrups
</title>
</head>
<body bgcolor="#FFFFFF">

  <p align="right"><b><font size="2" face="serif">Exhibit 10.8I</font></b></p>

<hr align="left" size="2" noshade>
<div style="page-break-before:always"></div>
<page>
<div style="margin-left:72%">
<p><img src="b323607x14x1.jpg" width="226" height="95"></p>
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0">
  <tr valign="top">
    <td><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font></td>
    <td width="20%" align="left"><font size="2" face="sans-serif"> <font face="sans-serif" size="1"><b>GlaxoSmithKline
      </b><br>
      One Franklin Plaza <br>
      P.O. Box 7929 <br>
      Philadelphia, PA <br>
      19101-7929<br>
      <br>
      </font><font size="1" face="sans-serif">Tel. 215 751 4000<br>
      Fax. 215 751 3400 <br>
      www.gsk.com</font></font></td>
  </tr>
</table>
<br>
<table width="100%" border="0" cellpadding="0" cellspacing="0">
  <tr valign="top">
    <td><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font><font size="2" face="sans-serif">&nbsp;</font></td>
    <td width="25%" align="left"><font size="2" face="sans-serif">August 1, 2001</font></td>
  </tr>
</table>
<p align="left"><font size="2" face="sans-serif">NPS Pharmaceuticals, Inc. <br>
  420 Chipeta Way<br>
  </font><font size="2" face="sans-serif">Salt Lake City, Utah 84108</font></p>
<p align="left"><font size="2" face="sans-serif">RE: Amendment Agreement to Amend the January 24, 2000 Amendment Agreement</font></p>
<p align="left"><font size="2" face="sans-serif">Dear Sirs:</font></p>
<div style="text-indent:3%"><font size="2" face="sans-serif">This Amendment Agreement
  to amend the January 24, 2000 Amendment Agreement will confirm that the Letter
  Agreement dated November 26, 1997 between NPS Pharmaceuticals, Inc., a corporation
  of the state of Delaware, having a place of business at 420 Chipeta Way, Salt
  Lake City, Utah 84108, U.S.A. (herein referred to as &#8220;NPS&#8221;) and
  SmithKline Beecham Corporation, a GlaxoSmithKline Company, a corporation of
  the Commonwealth of Pennsylvania, having a place of business at One Franklin
  Plaza, Philadelphia, Pennsylvania 19101, U.S.A. (hereinafter referred to as
  &#8220;GSK&#8221;) shall be amended, effective as of the date of NPS&#8217;
  signature below, as follows: </font></div>
<div style="margin-left:3%">
  <p><font size="2" face="sans-serif">&#149;&nbsp;&nbsp;&nbsp;In the second bullet, delete the
    &#8220;fifth, sixth, and seventh RESEARCH years&#8221; and insert therefor
    the words &#8220;fifth and sixth RESEARCH years, and at a level of one hundred
    seventy five thousand U.S. dollars (U.S. $175,000) per NPS FTE who is a lab
    personnel and at a level of one hundred fifty thousand U.S. dollars (U.S.
    $150,000) per NPS FTE who is a non-lab based consultant for the seventh RESEARCH
    year and at a level of two hundred twenty five thousand U.S. dollars (U.S.
    $225,000) per NPS FTE who is a non-lab based consultant for the eighth RESEARCH
    year, provided that it is understood that there will only be a total of two
    (2) NPS FTE&#8217;s during the seventh RESEARCH year and only a total of four
    (4) NPS FTE&#8217;s during the eighth RESEARCH year, and the levels outlined
    above will be applied on a pro-rata basis depending on the type of NPS FTE
    utilized.</font></p>
  <p>&#149;&nbsp;&nbsp;&nbsp;<font size="2" face="sans-serif">This Amendment Agreement shall be retroactively
    effective as of November 1, 2000.</font></p>
</div>
<div style="margin-left:3%">&#149;&nbsp;&nbsp;&nbsp;<font size="2" face="sans-serif">All other terms
  and conditions of the Letter Agreement shall remain in full force and effect.</font><br>
</div>
<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always">
  <page>
  <div style="text-indent:3%">
    <p><font size="2" face="sans-serif">Please indicate your acceptance of this January
      24, 2000 Amendment Agreement by signing and dating the duplicate copies
      of this letter below and returning one such fully executed copy to GSK.</font><br>
    </p>
  </div>
</div>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="70%">&nbsp;</td>
    <td colspan="2"><font size="2" face="sans-serif">Very truly yours,</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2"><font size="2" face="sans-serif">SMITHKLINE BEECHAM CORPORATION
      <br>
      (a GlaxoSmithKline Company)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="4%"><font size="2" face="sans-serif">By:</font></td>
    <td><font size="2" face="sans-serif"> <u>/s/ Donald F. Parman</u></font></td>
  </tr>

  <tr>
    <td>&nbsp;</td><td>&nbsp;</td>
    <td><font size="2" face="sans-serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Donald
      F. Parman</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="sans-serif"> Title: </font></td>
    <td><font size="2" face="sans-serif">Secretary</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="sans-serif">Date:</font></td>
    <td><font size="2" face="sans-serif">August 1, 2001</font></td>
  </tr>
</table>
<br>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td colspan="2"><font size="2" face="sans-serif">AGREED TO AND ACCEPTED: <br>
      NPS PHARMACEUTICALS, INC.</font></td>
    <td width="70%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td width="4%"><font size="2" face="sans-serif">By:</font></td>
    <td><font size="2" face="sans-serif"><u>/s/ E. F. Nemith</u></font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="sans-serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. F. Nemith</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="sans-serif">Title:</font></td>
    <td><font size="2" face="sans-serif">CSO</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="sans-serif">Date:</font></td>
    <td><font size="2" face="sans-serif">7 Aug 2001</font></td>
    <td>&nbsp;</td>
  </tr>
</table>
<br>
<hr noshade align="center" width="100%" size="2">
</body>
</html>


</TEXT>
</DOCUMENT>
